Kala-Azar as an AIDS-Related Opportunistic Infection
- 1 August 1999
- journal article
- review article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 13 (8) , 459-465
- https://doi.org/10.1089/108729199318183
Abstract
Visceral leishmaniasis (kala-azar) is a worldwide disseminated protozoal infection primarily transmitted by sand flies. Because host defense against this intracellular infection is T-cell-dependent, kala-azar has predictably joined the list of AIDS-related opportunistic infections in endemic areas. The vast majority of patients with AIDS-associated kala-azar are currently found in southern Europe (the Mediterranean basin, especially Spain in injection drug users); future cases will inevitably arise in other endemic regions including India, East Africa and Sudan, and Brazil. In CD4 cell-deficient HIV-infected individuals, kala-azar likely represents recrudescence of previously controlled asymptomatic infection; in drug users, newly acquired infection may result from transmission via shared needles. Coinfected patients are frequently parasitemic and may show atypical clinical presentations, unusual multi-organ involvement, and absent antileishmanial antibodies. Diagnosis is made by microscopic examination or culture of aspirate or biopsy of any involved tissue (primarily bone marrow) or by blood smear or culture. Conventional treatment (pentavalent antimonials) induces initial remission in about 50% of patients; amphotericin B and its new lipid formulations appear more active. If suppressive maintenance therapy is not used, relapse within 1 year is typical. In AIDS patients with a first episode of visceral kala-azar, up to 25% die within 1 month if treatment is stopped. Optimal primary and secondary prophylaxis for AIDS-related kala-azar remain to be determined; life-long maintenance therapy is becoming an accepted approach.Keywords
This publication has 25 references indexed in Scilit:
- VISCERAL LEISHMANIASIS (KALA-AZAR) IN TRANSPLANT RECIPIENTSTransplantation, 1998
- Kala-azar comes to New YorkArchives of internal medicine (1960), 1997
- Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patientsThe American Journal of Medicine, 1996
- rK39: A Cloned Antigen of Leishmania chagasi that Predicts Active Visceral LeishmaniasisThe Journal of Infectious Diseases, 1996
- Clinical Spectrum of LeishmaniasisClinical Infectious Diseases, 1996
- Immunochemotherapy for a Systemic Intracellular Infection: Accelerated Response Using Interferon- in Visceral LeishmaniasisThe Journal of Infectious Diseases, 1995
- Gastrointestinal Leishmaniasis in Human Immunodeficiency Virus-Infected Patients: Report of Five Cases and ReviewClinical Infectious Diseases, 1994
- Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidineAntimicrobial Agents and Chemotherapy, 1993
- Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smearsAIDS, 1993
- Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.Journal of Clinical Investigation, 1989